=> d l1
L1 HAS NO ANSWERS
L1 STR



VPA 24-9/10/11 U
NODE ATTRIBUTES:
NSPEC IS R AT 21
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 10 4
NUMBER OF NODES IS 26

STEREO ATTRIBUTES: NONE

=> s l1 ful
FULL SEARCH INITIATED 17:45:37 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2265 TO ITERATE

100.0% PROCESSED 2265 ITERATIONS 766 ANSWERS
SEARCH TIME: 00.00.01

L3 766 SEA SSS FUL L1

=> fil caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 182.04 182.25

FILE 'CAPLUS' ENTERED AT 17:45:42 ON 17 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 17 Jul 2008 VOL 149 ISS 3
FILE LAST UPDATED: 16 Jul 2008 (20080716/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l3
L4 15 L3

=> d bib abs 1-15

L4 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:1420376 CAPLUS
DN 148:24453
TI Treatment of gastrointestinal disorders with CGRP-antagonists
IN Doods, Henri; Arndt, Kirsten; Bouyssou, Thierry; Mueller, Stephan Georg; Rudolf, Klaus; Schaenzle, Gerhard
PA Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
SO PCT Int. Appl., 35pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007141285	A1	20071213	WO 2007-EP55543	20070606
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20080139591	A1	20080612	US 2007-760054	20070608
US 20080139537	A1	20080612	US 2007-760057	20070608
PRAI EP 2006-11787	A	20060608		

AB The invention relates to a method for preventing and treating visceral pain and gastrointestinal disorders such as functional bowel disorders and inflammatory bowel diseases through the use of effective amts. of a compound acting as CGRP antagonist. Twenty eight compds. are calimed (no data).
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:1176398 CAPLUS

DN 147:455648
TI New crystalline compounds of CGRP antagonists
IN Ries, Uwe; Sproll, Sonja; Werthmann, Ulrike; Zopf, Andreas; Huchler, Guenther
PA Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G., Germany
SO Ger. Offen., 68pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 102006017827	A1	20071018	DE 2006-102006017827	20060413
WO 2007118819	A2	20071025	WO 2007-EP53488	20070411
WO 2007118819	A3	20080529		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

US 20080086003	A1	20080410	US 2007-734520	20070412
PRAI DE 2006-102006017827	A	20060413		

AB The invention concerns novel crystalline compds. of CGRP antagonists that are prepared as salts of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, benzene sulfonic acid, p-toluene sulfonic acid, maleic acid, succinic acid, fumaric acid, D-(-)-tartaric acid, L-(+)-tartaric acid, naphthalene 2-sulfonic acid and naphthalene-1,5-disulfonic acid, their polymorph modifications, solvates and hydrates.

L4 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:376170 CAPLUS
DN 146:402012
TI Preparation of benzodiazepinones, quinolones, quinazolones, and related compounds as calcitonin gene-related peptide (CGRP) receptor antagonists
IN Mueller, Stephan Georg; Rudolf, Klaus; Lustenberger, Philipp; Schaenzle, Gerhard; Stenkamp, Dirk; Doods, Henri; Arndt, Kirsten
PA Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
SO PCT Int. Appl., 142pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007036533	A2	20070405	WO 2006-EP66789	20060927
WO 2007036533	A3	20070607		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

EP 1770087 A1 20070404 EP 2005-21282 20050929

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU

EP 1931646 A2 20080618 EP 2006-793855 20060927

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR

PRAI EP 2005-21282 A 20050929

WO 2006-EP66789 W 20060927

OS MARPAT 146:402012

GI



I



Q1



Q2



Q3

AB Title compds. [I; R1 = Q1, etc.; R2 = (substituted) Ph, pyridin-3-yl; R3 = Q2, Q3; X = N, C; R4 = Ph, pyridinyl; R5 = C(O)OR9; R6 = H, halo, OH, CF3, alkoxy; R7 = H, alkyl, etc.; R8 = a free electron pair if X = N or R8 = H, alkyl if X = C; R9 = H, alkyl, Ph, indanyl, etc.], tautomers, isomers, diastereomers, enantiomers, hydrates, mixts. salts and salt hydrates thereof, in particular salts thereof, which are physiol. compatible with acids or inorg. or organic bases, were prepared Thus, a solution of 4-(2-oxo-1,3,4,5-tetrahydro-1,3-benzodiazepin-3-yl)piperidin-1-carboxylic acid (R)-1-(4-amino-3-chloro-5-trifluoromethylbenzyl)-2-[4-(4-ethoxycarbonylphenyl)piperazin-1-yl]-2-oxoethylester (preparation given), TBTU and Et3N in DMF was stirred for 10 min at room temperature followed by stirring with Et 4-piperazin-1-ylbenzoate for 2 h to give 95% I [R1 = Q1; R6 = H; R2 = (4-amino-3-chloro-5-trifluoromethyl)phenyl; R3 = Q2; X = N; R7 = H; R8 = electron pair; R4 = Ph; R5 = 4-ethyloxycarbonyl]. Tested I showed affinity to human CGRP receptors with IC50 ≤10,000 nM.

L4 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:197982 CAPLUS

DN 146:274408

TI Preparation of N-(carbomethoxy)piperidines as CGRP antagonists

IN Mueller, Stephan Georg; Rudolf, Klaus; Lustenberger, Philipp; Schaenzle, Gerhard; Santagostino, Marco; Stenkamp, Dirk; Arndt, Kirsten; Doods, Henri

PA Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim

Pharma G.m.b.H. & Co. K.-G.
SO PCT Int. Appl., 377pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007020261	A2	20070222	WO 2006-EP65314	20060815
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
DE 102005038831	A1	20070222	DE 2005-102005038831	20050817
DE 102005050953	A1	20070426	DE 2005-102005050953	20051025
US 20070049581	A1	20070301	US 2006-462511	20060804
AU 2006281416	A1	20070222	AU 2006-281416	20060815
CA 2618834	A1	20070222	CA 2006-2618834	20060815
EP 1917256	A2	20080507	EP 2006-778243	20060815
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
MX 200801977	A	20080325	MX 2008-1977	20080211
KR 2008039990	A	20080507	KR 2008-706215	20080313
PRAI DE 2005-102005038831	A	20050817		
DE 2005-102005050953	A	20051025		
WO 2006-EP65314	W	20060815		

OS MARPAT 146:274408

GI



I



II

AB Title compds. I [X = R3-R4; R1 = substituted 3,4-dihydro-1H-quinazolin-2-ones, 1,3,4,5-tetrahydro-2H-benzo-1,3-diazepin-2-ones, etc.; R2 = 2-chloro-6-methylaniline, 2-chloro-6-(trifluoromethyl)aniline, etc.; R3 = substituted piperidines with provisos; R4 = substituted piperidines with provisos] and their pharmaceutically acceptable salts and formulations were prepared For example, N-(carbomethoxy)piperidine was prepared from 4-amino-3-chloro-5-trifluoromethylbenzaldehyde in 9-steps. In CGRP receptor binding assays, compds. I exhibited IC50 values ≤10000 nM.

L4 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:1173484 CAPLUS
DN 145:489283
TI N-Acylpiperidines and related compounds as CGRP-antagonists, methods for preparing them, pharmaceutical compositions and their use as pharmaceutical compositions
IN Mueller, Stephan Georg; Rudolf, Klaus; Lustenberger, Philipp; Stenkamp, Dirk; Santagostino, Marco; Paleari, Fabio; Schaenzle, Gerhard; Arndt, Kirsten; Doods, Henri
PA Boehringer Ingelheim International GmbH, Germany
SO U.S. Pat. Appl. Publ., 156pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20060252931	A1	20061109	US 2006-277177	20060322
	WO 2005092880	A1	20051006	WO 2005-EP3094	20050323
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	WO 2005103037	A2	20051103	WO 2005-EP4104	20050418
	WO 2005103037	A3	20060112		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1770091	A1	20070404	EP 2005-21283	20050929
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
PRAI	AR 2005-101139	A	20050323		
	WO 2005-EP3094	A	20050323		
	WO 2005-EP4104	A	20050418		

EP 2005-21283 A 20050929
DE 2004-102004015723 A 20040329
DE 2004-102004019492 A 20040422

OS MARPAT 145:489283

GI



I



II

AB The invention relates to the CGRP-antagonists of general formula I, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates, mixts. and salts thereof and the hydrates of the salts, particularly the physiol. acceptable salts thereof with inorg. or organic acids or bases, as well as those compds. of general formula I in which one or more hydrogen atoms are replaced by deuterium, pharmaceutical compns. containing these compds., the use thereof and processes for the preparation thereof. Compds. of formula I wherein X is CH2, NH, C1-3 alkyl-N, O and S; R1 is (spiro)substituted piperidine and oxodihydrothienopyrimidinyl; R2 is (un)substituted (un)fused aryl, and (un)substituted (un)fused pyridine; R3 is (un)substituted piperidine, (un)substituted piperazine, and (un)substituted diazepine; R4 is (un)substituted 4- to 7-membered oxycycloalkyl; and their tautomers and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by cyclization of 2-amino-3-methylphenol with CDI; the resulting 4-methyl-3H-benzoxazole-2-one underwent bromination to give 6-bromo-4-methyl-3H-benzoxazol-2-one, which underwent coupling with Me 2-acetylaminoacrylate to give Me 2-acetylamino-3-(4-methyl-2-oxo-2,3-dihydrobenzoxazol-6-yl)acrylate, which underwent hydrolysis to give 3-(4-methyl-2-oxo-2,3-dihydrobenzoxazole-6-yl)-2-oxopropionic acid, which underwent asym. reduction to give (R)-2-hydroxy-3-(4-methyl-2-oxo-2,3-dihydrobenzoxazol-6-yl)propionic acid, which underwent esterification to give the corresponding Me ester, which reacted with 4-nitrophenyl chloroformate and 3-(piperidin-4-yl)-1,3,4,5-tetrahydro-1,3-benzodiazepin-2-one followed by hydrolysis to give (R)-1-carboxy-2-(4-methyl-2-oxo-2,3-dihydrobenzoxazol-6-yl)ethyl 4-(2-oxo-1,3,4,5-tetrahydro-1,3-benzodiazepin-3-yl)piperidine-1-

carboxylate, which underwent amidation with 1-(tetrahydropyran-4-yl)piperazine to give compound II. All the invention compds. were evaluated for their CGRP binding affinity. The tested compds. exhibited IC50 values ≥ 10 000 nM.

L4 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:1005390 CAPLUS
DN 145:356814
TI Preparation of 2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-ylpiperidines and related compounds as CGRP receptor antagonists
IN Mueller, Stephan Georg; Rudolf, Klaus; Lustenberger, Philipp; Stenkamp, Dirk; Santagostino, Marco; Paleari, Fabio; Doods, Henri; Arndt, Kirsten; Schaenzle, Gerhard
PA Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
SO PCT Int. Appl., 231 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006100009	A1	20060928	WO 2006-EP2515	20060318
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	WO 2005092880	A1	20051006	WO 2005-EP3094	20050323
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	WO 2005103037	A2	20051103	WO 2005-EP4104	20050418
	WO 2005103037	A3	20060112		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

	EP 1770091	A1	20070404	EP 2005-21283	20050929
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
	AU 2006226615	A1	20060928	AU 2006-226615	20060318
	CA 2600909	A1	20060928	CA 2006-2600909	20060318
	EP 1863799	A1	20071212	EP 2006-723538	20060318
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	IN 2007DN06658	A	20070921	IN 2007-DN6658	20070828
	MX 200711527	A	20071019	MX 2007-11527	20070919
	CN 101146799	A	20080319	CN 2006-80009586	20070924
	KR 2007114831	A	20071204	KR 2007-724324	20071023
PRAI	WO 2005-EP3094	A	20050323		
	WO 2005-EP4104	A	20050418		
	EP 2005-21283	A	20050929		
	DE 2004-102004015723	A	20040329		
	DE 2004-102004019492	A	20040422		
	WO 2006-EP2515	W	20060318		

OS MARPAT 145:356814

GI



AB Title compds. I [X = CH2, NH, O, etc.; R1 = substituted 2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-ylpiperidines, etc.; R2 = 5-methylquinoxalines, 8-methylimidazo[1,2-a]pyridines, etc.; R3 = substituted piperidines, piperazines, etc.; R4 = 4 to 7-membered ocicycloalkyl ring with provisos] and their pharmaceutically acceptable salts and formulations were prepared For example, benzodiazepinylpiperidine II was prepared from 5-amino-m-cresol in 8-steps. In CGRP receptor inhibition assays, compds. I exhibited IC50 values ≤ 10000 nM.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:1005389 CAPLUS

DN 145:377393

TI Preparation of 2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-ylpiperidines as CGRP receptor antagonists

IN Mueller, Stephan Georg; Rudolf, Klaus; Lustenberger, Philipp; Stenkamp, Dirk; Santagostino, Marco; Paleari, Fabio; Dreyer, Alexander; Arndt, Kirsten; Doods, Henri; Schaenzle, Gerhard

PA Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.

SO PCT Int. Appl., 183 pp.
CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006100026	A1	20060928	WO 2006-EP2557	20060321
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	WO 2005092880	A1	20051006	WO 2005-EP3094	20050323
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2006226544	A1	20060928	AU 2006-226544	20060321
	CA 2600189	A1	20060928	CA 2006-2600189	20060321
	EP 1863791	A1	20071212	EP 2006-723571	20060321
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BA, HR, YU				
	NO 2007003758	A	20071019	NO 2007-3758	20070719
	MX 200711526	A	20071019	MX 2007-11526	20070919
	CN 101146790	A	20080319	CN 2006-80009598	20070924
	KR 2007113317	A	20071128	KR 2007-724261	20071022
PRAI	WO 2005-EP3094	A	20050323		
	DE 2004-102004015723	A	20040329		
	WO 2006-EP2557	W	20060321		

OS MARPAT 145:377393

GI



I

II

AB Title compds. I [B = substituted Ph, phenols, anilines, etc.; Y = C, N; R3 = cyclopentyl, cyclohexyl, cycloheptyl; R4 = H with provisos] and their pharmaceutically acceptable salts were prepared For example, benzodiazepinylpiperidine II was prepared from 3-trifluoromethylbenzaldehyde in 7-steps. In CGRP receptor inhibition assays, compds. I exhibited IC50 values ≤ 10000 nM.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:656692 CAPLUS
DN 145:96491
TI Use of CGRP antagonists in treatment and prevention of hot flushes in prostate cancer patients
IN Rudolf, Klaus; Doods, Henri; Mueller, Stephan Georg; Zamponi, Annette; Lustenberger, Philipp; Stenkamp, Dirk; Arndt, Kirsten; Schaenzle, Gerhard; Brickl, Rolf-Stefan
PA Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
SO PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006069754	A1	20060706	WO 2005-EP13974	20051223
WO 2006069754	A9	20070809		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
DE 102004063755	A1	20060720	DE 2004-102004063755	20041229
US 20060154921	A1	20060713	US 2005-301422	20051213

CA 2592278 A1 20060706 CA 2005-2592278 20051223
EP 1833484 A1 20070919 EP 2005-843728 20051223
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
US 20070249592 A1 20071025 US 2007-774995 20070709
PRAI DE 2004-102004063755 A 20041229
US 2005-301422 A1 20051213
WO 2005-EP13974 W 20051223
AB The invention discloses a method for treatment or prevention of hot flushes in men who underwent castration, e.g. due to androgen ablation treatment in prostate cancer therapy, comprising administration of an effective amount of a selected CGRP antagonist to the patient, as well as the use of the active compds. for the manufacture of a pharmaceutical composition intended to be used in this method.
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:636811 CAPLUS
DN 145:76714
TI Use of selected CGRP antagonists for combating menopausal hot flushes
IN Rudolf, Klaus; Doods, Henri; Mueller, Stephan Georg; Zamponi, Annette; Lustenberger, Philipp; Arndt, Kirsten; Schaenzle, Gerhard; Stenkamp, Dirk; Brickl, Rolf-Stefan
PA Boehringer Ingelheim International GmbH, Germany
SO U.S. Pat. Appl. Publ., 21 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20060142274	A1	20060629	US 2005-301446	20051213
DE 102004063752	A1	20060713	DE 2004-102004063752	20041229
CA 2594097	A1	20060713	CA 2005-2594097	20051223
WO 2006072415	A1	20060713	WO 2005-EP13972	20051223

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

EP 1833483 A1 20070919 EP 2005-823294 20051223
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
PRAI DE 2004-102004063752 A 20041229
WO 2005-EP13972 W 20051223
AB The invention discloses the use of selected CGRP antagonists, the physiol. acceptable salts thereof or the hydrates or the hydrates of the salts thereof for combating menopausal hot flushes. A variety of formations are included.

L4 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:636805 CAPLUS

DN 145:96481
TI Use of selected CGRP antagonists in combination with other antimigraine drugs for the treatment of migraine
IN Rudolf, Klaus; Doods, Henri; Mueller, Stephan Georg; Zamponi, Annette; Lustenberger, Philipp; Arndt, Kirsten; Schaenzle, Gerhard; Stenkamp, Dirk; Brickl, Rolf-Stefan
PA Boehringer Ingelheim International GmbH, Germany
SO U.S. Pat. Appl. Publ., 22 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20060142273	A1	20060629	US 2005-275169	20051216
	DE 102004063753	A1	20060713	DE 2004-102004063753	20041229
	CA 2594096	A1	20060713	CA 2005-2594096	20051223
	WO 2006072413	A1	20060713	WO 2005-EP13964	20051223
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	EP 1833478	A1	20070919	EP 2005-823228	20051223
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	US 20080103134	A1	20080501	US 2007-962633	20071221
PRAI	DE 2004-102004063753	A	20041229		
	US 2005-275169	B1	20051216		
	WO 2005-EP13964	W	20051223		

AB The invention discloses a process for the treatment or prevention of indications which are selected from among the group comprising headaches, migraine and cluster headaches, the process comprising the joint administration of a therapeutically effective amount of a selected CGRP antagonist (A), a physiol. acceptable salt thereof or a hydrate of the salt and a therapeutically effective amount of a second or third active anti-migraine medicament (B), particularly sumatriptan, zolmitriptan, or dihydroergotamine, or a physiol. acceptable salt thereof, as well as the corresponding pharmaceutical compns. and the preparation thereof. A variety of formulations are included.

L4 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:1154551 CAPLUS
DN 143:422350
TI Preparation of 1,3-dihydro-3-(4-piperidinyl)-2H-imidazo[4,5-c]quinolin-2-ones and related compounds as cgrp antagonists
IN Rudolf, Klaus; Mueller, Stephan Georg; Lustenberger, Philipp; Stenkamp, Dirk; Schaenzle, Gerhard; Arndt, Kirsten; Doods, Henri
PA Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma Gmbh & Co. KG
SO PCT Int. Appl., 185 pp.
CODEN: PIXXD2
DT Patent
LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005100352	A1	20051027	WO 2005-EP3759	20050409
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 102004018796	A1	20051103	DE 2004-102004018796	20040415
	CA 2563386	A1	20051027	CA 2005-2563386	20050409
	EP 1737860	A1	20070103	EP 2005-729383	20050409
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BA, HR, YU				
	JP 2007532601	T	20071115	JP 2007-507727	20050409
	US 20050250763	A1	20051110	US 2005-107052	20050415
PRAI	DE 2004-102004018796	A	20040415		
	US 2004-569948P	P	20040511		
	WO 2005-EP3759	W	20050409		

OS MARPAT 143:422350
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = substituted Ph, i.e., CF3, NH2, Cl, etc.; X = O, CH2, NH; R1 = 1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-onyl, 1,3-dihydro-2H-benzimidazol-2-one, etc.; NR2R3 = 1,4'-bipiperidinyl, 1-methyl-4-(4-piperidinyl)piperazinyl, 1-(1-methyl-4-piperidinyl)piperazinyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared For example, coupling of 1,4'-bipiperidine and acid II afforded imidazo[4,5-c]quinolin-2-one III in 76% yield. In human cgrp receptor assays, compds. I exhibited IC50 values ≤ 1000 nM.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:1152762 CAPLUS
DN 143:440448
TI Preparation of 3-piperidin-4-yl-1,3,4,5-tetrahydro-1,3-benzdiazepin-2-ones and related compounds as CGRP antagonists
IN Mueller, Stephan Georg; Rudolf, Klaus; Lustenberger, Philipp; Stenkamp, Dirk; Arndt, Kirsten; Doods, Henri; Schaenzle, Gerhard
PA Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G., Germany
SO Ger. Offen., 51 pp.
CODEN: GWXXBX
DT Patent
LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI DE 102004018795 A1 20051027 DE 2004-102004018795 20040415
CA 2562526 A1 20051027 CA 2005-2562526 20050409
WO 2005100343 A1 20051027 WO 2005-EP3741 20050409
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
EP 1737842 A1 20070103 EP 2005-731650 20050409
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BA, HR, YU
JP 2007532600 T 20071115 JP 2007-507723 20050409
US 20050282857 A1 20051222 US 2005-107195 20050415
US 20070238715 A1 20071011 US 2007-688123 20070319
PRAI DE 2004-102004018795 A 20040415
US 2004-570005P P 20040511
WO 2005-EP3741 W 20050409
US 2005-107195 B1 20050415
OS MARPAT 143:440448
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = substituted Ph, i.e., CF3, NH2, Cl, etc.; X = O, CH2, NH; R1 = 3,4-dihydro-2(1H)-quinazolinonyl, 1,3,4,5-tetrahydro-2H-benzo-1,3-diazepin-2-onyl; NR2R3 = 1,4'-bipiperidinyl, 1-methyl-4-(4-piperidinyl)piperazinyl, 1-(1-methyl-4-piperidinyl)piperazinyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared For example, coupling of 4-(2-piperidin-1-yl-ethyl)piperidine and acid II afforded benzdiazepin-2-one III in 64% yield. In human cgrp receptor assays, compds. I exhibited IC50 values ≤ 1000 nM.

L4 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:1075789 CAPLUS
DN 143:367334
TI Preparation of 3-piperidin-4-yl-1,3,4,5-tetrahydro-1,3-benzdiazepin-2-ones as OCGRP receptor antagonists
IN Mueller, Stephan Georg; Rudolf, Klaus; Lustenberger, Philipp; Stenkamp, Dirk; Dreyer, Alexander; Arndt, Kirsten; Doods, Henri; Schaenzle, Gerhard; Santagostino, Marco; Paleari, Fabio
PA Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
SO PCT Int. Appl., 318 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 6

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005092880	A1	20051006	WO 2005-EP3094	20050323
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,
SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

DE 102004015723 A1 20051020 DE 2004-102004015723 20040329
AU 2005225539 A1 20051006 AU 2005-225539 20050323
CA 2558889 A1 20051006 CA 2005-2558889 20050323
EP 1732917 A1 20061220 EP 2005-741783 20050323
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BA, HR, YU
CN 1976916 A 20070606 CN 2005-80017545 20050323
BR 2005009368 A 20070911 BR 2005-9368 20050323
JP 2007530617 T 20071101 JP 2007-505453 20050323
US 20050234067 A1 20051020 US 2005-93834 20050329
AU 2006226615 A1 20060928 AU 2006-226615 20060318
CA 2600909 A1 20060928 CA 2006-2600909 20060318
WO 2006100009 A1 20060928 WO 2006-EP2515 20060318
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM
EP 1863799 A1 20071212 EP 2006-723538 20060318
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
AU 2006226544 A1 20060928 AU 2006-226544 20060321
CA 2600189 A1 20060928 CA 2006-2600189 20060321
WO 2006100026 A1 20060928 WO 2006-EP2557 20060321
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM
EP 1863791 A1 20071212 EP 2006-723571 20060321
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BA,
HR, YU
US 20060252750 A1 20061109 US 2006-277175 20060322
US 20060252931 A1 20061109 US 2006-277177 20060322
NO 2006004166 A 20061025 NO 2006-4166 20060914
MX 2006PA11145 A 20061129 MX 2006-PA11145 20060928

	KR 2007007867	A	20070116	KR 2006-722593	20061027
	NO 2007003758	A	20071019	NO 2007-3758	20070719
	IN 2007DN06658	A	20070921	IN 2007-DN6658	20070828
	MX 200711526	A	20071019	MX 2007-11526	20070919
	MX 200711527	A	20071019	MX 2007-11527	20070919
	CN 101146799	A	20080319	CN 2006-80009586	20070924
	CN 101146790	A	20080319	CN 2006-80009598	20070924
	KR 2007113317	A	20071128	KR 2007-724261	20071022
	KR 2007114831	A	20071204	KR 2007-724324	20071023
PRAI	DE 2004-102004015723	A	20040329		
	US 2004-566394P	P	20040429		
	AR 2005-101139	A	20050323		
	WO 2005-EP3094	W	20050323		
	WO 2005-EP4104	A	20050418		
	EP 2005-21283	A	20050929		
	WO 2006-EP2515	W	20060318		
	WO 2006-EP2557	W	20060321		

OS MARPAT 143:367334
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = O, S; X = O, S; D, E = CH, N with provisos; G = CRa; M = CRb; Q = CRc; Ra, Rb, Rc = H, halo, alkyl, etc.; R1 = 5 to 7-membered heterocycle; R2 = H, Ph, pyridinyl, etc.; R3 = H, Ph, pyridinyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared For example, coupling of 1-(1-methylpiperidin-4-yl)piperazine and carboxylic acid II afforded benzdiazepine III in 87% yield. In human OCGRP receptor inhibition assays, compds. I exhibited IC50 values ≤ 10000 nM.
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:370923 CAPLUS
DN 140:391302
TI Preparation of benzo-1,3-diazepin-2-ones and related compounds as CGRP receptor antagonists for the treatment of migraine headaches
IN Rudolf, Klaus; Mueller, Stephan Georg; Stenkamp, Dirk; Lustenberger, Philipp; Dreyer, Alexander; Bauer, Eckhart; Schindler, Marcus; Arndt, Kirsten; Doods, Henri
PA Boehringer Ingelheim, Germany
SO PCT Int. Appl., 254 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004037811	A1	20040506	WO 2003-EP11763	20031023
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,				

BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	DE 10250082	A1	20040513	DE 2002-10250082	20021025
	US 20040132716	A1	20040708	US 2003-685921	20031015
	CA 2503462	A1	20040506	CA 2003-2503462	20031023
	AU 2003276157	A1	20040513	AU 2003-276157	20031023
	EP 1558601	A1	20050803	EP 2003-809318	20031023
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003015642	A	20050830	BR 2003-15642	20031023
	CN 1708492	A	20051214	CN 2003-80101980	20031023
	JP 2006505573	T	20060216	JP 2004-545964	20031023
	NZ 540006	A	20070531	NZ 2003-540006	20031023
	ZA 2005002247	A	20050919	ZA 2005-2247	20050317
	MX 2005PA04188	A	20051005	MX 2005-PA4188	20050420
	IN 2005DN01641	A	20070119	IN 2005-DN1641	20050421
	NO 2005002493	A	20050524	NO 2005-2493	20050524
	IN 2006DN05460	A	20070803	IN 2006-DN5460	20060920
	US 20070244099	A1	20071018	US 2007-757743	20070604
PRAI	DE 2002-10250082	A	20021025		
	US 2002-426167P	P	20021114		
	US 2003-685921	B1	20031015		
	WO 2003-EP11763	W	20031023		
	DE 2004-102004015723	A	20040329		

OS MARPAT 140:391302
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = O, S, phenylsulfonylimino, etc.; X = O, S, substituted imino, etc.; Y, Z = alkyl, difluoromethyl, trifluoromethyl, etc.; R1 = 5-7 membered aza, diaza, triaza, etc. heterocycle; R2 = H, phenylmethyl, alkyl, etc.; R3 = H, Ph, pyridinyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared For example, benzo-1,3-diazepin-2-one II was prepared from 1-(3,4-diethylphenyl)ethanone in 8-steps. In human CGRP receptor binding affinity assays, compds. I exhibited IC50 values < 10000 nM. Compds. I are claimed useful for the treatment of migraine headaches.
RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:370922 CAPLUS
DN 140:391301
TI Preparation of benzo-1,3-diazepin-2-ones and related compounds as CGRP receptor antagonists for the treatment of migraine headaches
IN Rudolf, Klaus; Mueller, Stephan Georg; Stenkamp, Dirk; Lustenberger, Philipp; Dreyer, Alexander; Bauer, Eckhart; Schindler, Marcus; Kirsten, Arndt; Doods, Henri
PA Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G., Germany
SO PCT Int. Appl., 315 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004037810	A1	20040506	WO 2003-EP11762	20031023
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

```
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
             GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
             LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
             OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
             TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     DE 10250080          A1    20040513    DE 2002-10250080        20021025
     US 20060079504       A1    20060413    US 2003-687262          20031016
     CA 2503455           A1    20040506    CA 2003-2503455         20031023
     AU 2003276156        A1    20040513    AU 2003-276156          20031023
     EP 1558600           A1    20050803    EP 2003-809317          20031023
     EP 1558600           B1    20080507
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     BR 2003015665        A     20050830    BR 2003-15665           20031023
     CN 1708493           A     20051214    CN 2003-80102004        20031023
     JP 2006516244        T     20060629    JP 2004-545963          20031023
     NZ 540051            A     20080229    NZ 2003-540051          20031023
     AT 394392            T     20080515    AT 2003-809317          20031023
     ZA 2005002248        A     20060830    ZA 2005-2248            20050317
     IN 2005DN01640       A     20070323    IN 2005-DN1640          20050421
     MX 2005PA04375       A     20050705    MX 2005-PA4375          20050425
     NO 2005002496        A     20050624    NO 2005-2496            20050524
PRAI DE 2002-10250080     A     20021025
     US 2002-426168P      P     20021114
     WO 2003-EP11762      W     20031023
OS   MARPAT 140:391301
GI
```



```
* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *
```


```
AB   Title compds. I [A = O, S, phenylsulfonylimino, etc.; X = O, S,
     substituted imino, etc.; U = alkyl, alkenyl, alkynyl, etc.; V = Cl, Br,
     amino, etc.; W = H, halo, difluoromethyl, etc.; R1 = 5-7 membered aza,
     diaza, triaza, etc. heterocycle; R2 = H, phenylmethyl, alkyl, etc.; R3 =
     H, Ph, pyridinyl, etc.] and their pharmaceutically acceptable salts and
     formulations were prepared  For example, benzo-1,3-diazepin-2-one II was
     prepared from 4-amino-3-chloro-5-trifluoromethylbenzoic acid in 9-steps.  In
     human CGRP receptor binding affinity assays, compds. I exhibited IC50
     values < 10000 nM.  Compds. I are claimed useful for the treatment of
     migraine headaches.
```


```
RE.CNT  3     THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> d hitstr 15

L4   ANSWER 15 OF 15  CAPLUS  COPYRIGHT 2008 ACS on STN
IT   688019-33-2P
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
     (Uses)
        (preparation of benzo-1,3-diazepin-2-ones and related compds. as CGRP
        receptor antagonists for the treatment of migraine headaches)
RN   688019-33-2  CAPLUS
```

CN 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[[4-amino-3-chloro-5-(trifluoromethyl)phenyl]methyl]-2-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]-2-oxoethyl ester (CA INDEX NAME)

Absolute stereochemistry.